Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study

(2019) Mette Deleuran et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma

(2019) Jonathan Corren et al.   Journal of Allergy and Clinical Immunology-In Practice

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

(2019) Audrey Le Floc’h et al.   ALLERGY

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

(2018) Klaus F. Rabe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

(2018) Mario Castro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Commonality of the IL-4/IL-13 pathway in atopic diseases

(2017) Namita A. Gandhi et al.   Expert Review of Clinical Immunology

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

(2016) Sally Wenzel et al.   LANCET

Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis

(2016) Peter Lange et al.   Lancet Respiratory Medicine

Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes

(2014) L. E. Macdonald et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

(2014) A. J. Murphy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exploring the Effects of Omalizumab in Allergic Asthma

(2013) Nicola A. Hanania et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET